According to Syndax Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.59877. At the end of 2022 the company had a P/E ratio of -10.4.
Year | P/E ratio | Change |
---|---|---|
2022 | -10.4 | -120.41% |
2021 | 50.9 | -530.33% |
2020 | -11.8 | 149.26% |
2019 | -4.75 | 210.35% |
2018 | -1.53 | -49.55% |
2017 | -3.03 | 100.81% |
2016 | -1.51 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | -4.44 | -48.41% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.